/
NTRB
$3.21+$0.15 (+4.90%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$37.2M
12M shares
52-week range
$2.90 – $11.68
4% from low
Sector
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Exchange
NASDAQ
CS
Borrow rate
2.24%
Moderate
Price (6 mo)
Loading chart…
Change$-2.52
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $245.3K | $370.6K | $943.7K | $1.4M | $2.1M | $2.1M | $2.1M | $2.0M |
| Cost of revenue | $288.3K | $549.1K | $582.4K | $917.8K | $1.3M | $1.2M | $1.4M | $1.5M |
| Gross profit | −$43.0K | −$178.5K | $361.3K | $504.3K | $750.4K | $862.1K | $699.3K | $566.3K |
| Gross margin | -17.5% | -48.1% | 38.3% | 35.5% | 36.1% | 41.3% | 32.7% | 27.8% |
| R&D | $0 | $0 | $0 | $411.4K | $982.2K | $2.0M | $3.1M | $1.9M |
| Operating income | −$3.3M | −$2.0M | −$2.6M | −$3.9M | −$4.1M | −$4.9M | −$6.7M | −$8.3M |
| EBITDA | −$3.3M | −$2.6M | −$2.5M | −$5.7M | −$4.1M | −$5.1M | −$10.2M | −$8.0M |
| Net income | −$3.3M | −$2.8M | −$3.2M | −$8.4M | −$4.8M | −$5.5M | −$10.5M | −$8.2M |
| Net margin | -1358.1% | -754.1% | -340.5% | -592.2% | -231.3% | -263.0% | -489.9% | -404.1% |
| EPS (diluted) | -0.53 | -0.44 | -0.48 | -1.06 | -0.57 | -0.69 | -0.99 | -2.58 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $95M | $1.57 | $1.57–$1.57 | 1 |
| 2028 | $180M | $3.66 | $3.66–$3.66 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Nutriband Inc. Common Stock
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
www.nutriband.com- Employees
- 3
- IPO / List date
- Jun 20, 2017
- HQ
- ORLANDO, FL
Held by traders on TradeandTell
No one on the platform currently holds NTRB.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in NTRB as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2022-08-12 | 7-for-6 |
| 2019-07-24 | 1-for-4reverse |
Recent trades on TradeandTell
No one on the platform has traded NTRB yet.
